Regulatory dendritic cell therapy in organ transplantation DOI
Yannis Hadjiyannis, Angus W. Thomson

Current Opinion in Organ Transplantation, Год журнала: 2023, Номер 29(2), С. 121 - 130

Опубликована: Ноя. 22, 2023

Purpose of review Regulatory dendritic cells (DCregs; also ‘tolerogenic DCs’), innate immune that regulate the alloimmune response, are a novel cellular therapy for organ transplantation. Preliminary results from early-phase clinical trials in live donor kidney and liver transplantation promising. This follows many years research elucidating mechanisms action utility DCregs. Herein, we trial observations recent advances production, modification, future-trajectory DCreg Recent findings Preclinical work has demonstrated ability adoptively transferred to abrogate ischemia-reperfusion injury promote long-term allograft survival. Good Manufacturing Practice-grade DCregs have been generated adequate numbers autologous donor-derived These feasibility safety, with preliminary evidence an influence on host reactivity. In both transplantation, reduced effector CD8 + T-cells noted, together other changes may be conducive dependence immunosuppressive therapy. Summary Substantial progress made bringing testing Additional mechanistic studies now needed further explore garner full potential

Язык: Английский

Mechanisms and therapeutic strategies of immune checkpoint molecules and regulators in type 1 diabetes DOI Creative Commons

Jiatong Ding,

Kangping Yang,

Kong-Lan Lin

и другие.

Frontiers in Endocrinology, Год журнала: 2023, Номер 13

Опубликована: Янв. 10, 2023

Background Considered a significant risk to health and survival, type 1 diabetes (T1D) is heterogeneous autoimmune disease characterized by hyperglycemia caused an absolute deficiency of insulin, which mainly due the immune-mediated destruction pancreatic beta cells. Scope review In recent years, role immune checkpoints in treatment cancer has been increasingly recognized, but unfortunately, little attention paid they play both development secondary with checkpoint inhibitors T1D, such as cytotoxic T-lymphocyte antigen 4(CTLA-4), programmed cell death protein-1(PD-1), lymphocyte activation gene-3(LAG-3), ligand-1(PD-L1), T-cell immunoglobulin mucin protein-3(TIM-3). Here, this summarizes research on mechanisms diverse molecules mediating T1D their potential theoretical basis for prevention diabetes. Major conclusions Immune related diabetes, similar are severe endocrine toxicity induced inhibitors. Interestingly, numerous measures show excellent efficacy via regulating molecules, including co-inhibitory co-stimulatory molecules. Thus, targeting may exhibit improve clinical outcomes.

Язык: Английский

Процитировано

14
Regulatory dendritic cell therapy in organ transplantation DOI
Yannis Hadjiyannis, Angus W. Thomson

Current Opinion in Organ Transplantation, Год журнала: 2023, Номер 29(2), С. 121 - 130

Опубликована: Ноя. 22, 2023

Purpose of review Regulatory dendritic cells (DCregs; also ‘tolerogenic DCs’), innate immune that regulate the alloimmune response, are a novel cellular therapy for organ transplantation. Preliminary results from early-phase clinical trials in live donor kidney and liver transplantation promising. This follows many years research elucidating mechanisms action utility DCregs. Herein, we trial observations recent advances production, modification, future-trajectory DCreg Recent findings Preclinical work has demonstrated ability adoptively transferred to abrogate ischemia-reperfusion injury promote long-term allograft survival. Good Manufacturing Practice-grade DCregs have been generated adequate numbers autologous donor-derived These feasibility safety, with preliminary evidence an influence on host reactivity. In both transplantation, reduced effector CD8 + T-cells noted, together other changes may be conducive dependence immunosuppressive therapy. Summary Substantial progress made bringing testing Additional mechanistic studies now needed further explore garner full potential

Язык: Английский

Процитировано

4